PharVision Advisers’s CVRx CVRX Stock Holding History

PharVision Advisers’s Portfolio CVRX Stock Details CVRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,480	Closed	-$259K	–	324
2024 Q4	$259K	Buy	+20,480	New	+$253K	0.22%	201

Other funds holding CVRX

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

PharVision Advisers's CVRX Position: Q1 2025 in Review

PharVision Advisers sold out of CVRx (CVRX) in Q1 2025, closing a stake of 20,480 shares — an estimated $259K sold.

PharVision Advisers first reported a position in CVRX in Q4 2024 and held it in 1 quarter. The position peaked at $259K in Q4 2024. 96 funds tracked by Wall St. Rank hold CVRX as of Q1 2025.

PharVision Advisers reported no remaining CVRx position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 20,480 CVRx shares in Q1 2025, an estimated $259K.
PharVision Advisers first reported a position in CVRx in Q4 2024 and held it in 1 quarter.
PharVision Advisers's CVRx position peaked at $259K in Q4 2024.
96 funds tracked by Wall St. Rank held CVRx as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.